Kyowa Kirin and Orchard Therapeutics have entered into a definitive agreement in which Kyowa Kirin will acquire Orchard Therapeutics.
This acquisition will enable Kyowa Kirin to enhance the value of Libmeldy® and expedite the advancement of Orchard Therapeutics' next-in-line MPS programmes, as well as its early research initiatives, including genetic Crohn’s disease and frontotemporal dementia (FTD).
The collaboration between Orchard Therapeutics' innovative HSC gene therapy platform and Kyowa Kirin's capabilities and resources will facilitate the ongoing development of numerous promising biopharmaceutical candidates. These candidates have the potential to transform medical care and provide life-changing benefits, particularly in therapeutic areas such as oncology and autoimmune diseases.
Upon the completion of this acquisition, Kyowa Kirin will position itself as a global leader in the rapidly expanding field of genetic medicine. This can be achieved through the acquisition of a comprehensive portfolio that encompasses commercial, clinical, and pre-clinical haematopoietic stem cell (HSC) gene therapies. These therapies have been specifically developed to target severe diseases affecting patients and their families.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!